Press release
Peanut Allergy Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Peanut Allergy Treatment Landscape. Click here to read more @ Peanut Allergy Pipeline Outlook [https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Peanut Allergy Pipeline Report
* In August 2025, DBV Technologies announced a Phase 3 randomized double-blind, placebo-controlled (DBPC) study of 6-months duration to assess the safety of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE).
* DelveInsight's Peanut Allergy Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Peanut Allergy treatment.
* The leading Peanut Allergy Companies such as DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix , and others.
* Promising Peanut Allergy Pipeline Therapies such as Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.
Discover groundbreaking developments in Peanut Allergy therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Peanut Allergy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Peanut Allergy Emerging Drugs Profile
* DBV712: DBV Technologies
DBV712 is an investigational epicutaneous immunotherapy (EPIT) product developed by DBV Technologies for the treatment of peanut allergy. It consists of a patch that delivers microgram amounts of peanut protein through the skin, aiming to desensitize the immune system over time and reduce allergic reactions upon accidental exposure. DBV712 is designed for daily application on the back, leveraging the skin's immune properties to induce tolerance with a favorable safety profile. This non-invasive approach offers a convenient alternative to oral immunotherapy, particularly for pediatric patients. Currently, the drug is in Phase III stage of its development for the treatment of Peanut Allergy.
* PVX-108: Aravax Pty Ltd
PVX108 comprises a mixture of peptides that represent sequences from peanut allergens which are critical for recognition by peanut-specific T cells. Unlike other peanut allergy immunotherapies, PVX108 does not contain the peanut proteins (allergens) which cause severe allergic reactions. PVX108 is being developed as a safe and simple therapy to restore and maintain tolerance, and reduce the risk of severe allergic reactions upon accidental exposure to peanuts. PVX108 therefore offers several advantages over other approaches. It has negligible risk of activating basophils and mast cells in people with peanut allergy. It does not require careful dose escalation or daily administration. It retrains the immune system to restore and maintain tolerance, reducing the risk of anaphylaxis. PVX108 does not contain natural extracts or whole allergens and has been engineered to be incapable of triggering acute allergic reactions. It has been designed to provide a safe, convenient and long-lasting treatment with monthly dosing through essentially needle-free intradermal administration. Currently, the drug is in Phase II stage of its development for the treatment of Peanut Allergy.
* INP20: InnoUp Farma S.L.
INP20 is an innovative oral vaccine developed by InnoUp Farma for the treatment of peanut allergy. Utilizing proprietary nanoparticle technology, INP20 encapsulates whole peanut extract to deliver controlled release directly in the gut, minimizing systemic absorption and reducing the risk of severe allergic reactions. The formulation is designed to mask allergens from immune detection while simultaneously promoting immunomodulation by targeting antigen-presenting cells. This dual mechanism offers a promising approach to induce long-term tolerance in peanut-allergic individuals, with a clean safety profile and simplified dosing. Currently, the drug is in Phase I/II stage of its development for the treatment of Peanut Allergy.
The Peanut Allergy Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Peanut Allergy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peanut Allergy Treatment.
* Peanut Allergy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Peanut Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peanut Allergy market
Stay informed about the Peanut Allergy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Peanut Allergy Unmet Needs [https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Peanut Allergy Companies
DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix , and others.
Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Peanut Allergy Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Peanut Allergy Pipeline! See the latest progress in drug development and clinical research @ Peanut Allergy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Peanut Allergy Pipeline Report
* Coverage- Global
* Peanut Allergy Companies- DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix , and others.
* Peanut Allergy Pipeline Therapies- Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301 , and others.
* Peanut Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Peanut Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Immunological and Autoimmune Disorders Research-Access the Full Peanut Allergy Pipeline Analysis Today! @ Peanut Allergy Drugs and Companies [https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Peanut Allergy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Peanut Allergy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* DBV712: DBV Technologies
* Mid Stage Products (Phase II)
* PVX-108: Aravax Pty Ltd
* Early Stage Products (Phase I/II)
* INP20: InnoUp Farma S.L.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Peanut Allergy Key Companies
* Peanut Allergy Key Products
* Peanut Allergy- Unmet Needs
* Peanut Allergy- Market Drivers and Barriers
* Peanut Allergy- Future Perspectives and Conclusion
* Peanut Allergy Analyst Views
* Peanut Allergy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peanut-allergy-pipeline-outlook-report-2025-key-10-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peanut Allergy Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4148520 • Views: …
More Releases from ABNewswire
Ilana McBain Launches Limited Edition Fine Art Print Series as Her Profile Rises …
Sunshine Coast artist Ilana McBain has launched a new series of Limited Edition Fine Art Prints featuring 20 variations, each capped at only 100 editions worldwide. Hand-signed, individually numbered, and produced on museum-grade archival paper, the collection reflects McBain's rising profile and growing international collector base. The series showcases her bold, contemporary style and is available now through her online shop.
SUNSHINE COAST, QLD - Australian multidisciplinary artist Ilana McBain today…
Dualentry Explains Why AI Won't Replace Accountants but Will Transform Accountin …
Ask CFOs if artificial intelligence will eliminate their departments, and you'll trigger an immediate defensive reaction.
Of course not; someone needs to ensure compliance, interpret complex standards, make judgment calls. Yet while they're defending their teams, something remarkable is happening: JPMorgan Chase just eliminated 360,000 hours of annual legal document review work with a single AI platform.
PwC announced a $1 billion three-year investment to expand and scale its AI capabilities, including…
Combat Veteran-Physician's MedEq Fitness Empowers Holiday Health Transformations …
MedEq Fitness's complete wellness ecosystem, from hyperbaric chambers to ice plunges, captures holiday market after generating $250,000 in first 90 days. The physician-combat veteran founder's personal long COVID recovery story drives mission to democratize advanced wellness technology.
MedEq Fitness transforms the landscape of home wellness following its remarkable $250,000 revenue generation in just 90 days, as the physician and combat veteran-founded company capitalizes on surging holiday demand for comprehensive health solutions…
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Co …
DelveInsight's "Marginal Zone Lymphoma Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's…
More Releases for Allergy
Allergy Shots Market | ALK Abello, Aimmune Therapeutics, Allergy Therapeutics, A …
The global allergy shots market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the allergy shots market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Allergy Shots Market: Rising Demand and Advancements in Allergy Treatment
Market Overview:
The Allergy Shots market refers to the production, distribution, and utilization of immunotherapy treatments known as allergy shots or allergen immunotherapy. Allergy shots are a form of treatment for allergies, particularly for allergic rhinitis (hay fever), allergic asthma, and insect sting allergies. They involve the administration of gradually increasing doses of allergens, such as pollen, dust mites, pet dander, or insect venom, to desensitize the immune system and…
Allergy Treatment Market Increasing Demand By Allergy Type: Eye Allergy, Rhiniti …
Acumen Research and Consulting has announced the addition of the "Allergy Treatment Market” report to their offering.
The Allergy Treatment Market Report 2018 is an in depth study analyzing the current state of the Allergy Treatment Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Allergy Treatment Market provides analysis of China market covering the industry trends, recent…
Allergy Immunotherapy Market to Witness Huge Growth by Key Players: Allergy Ther …
According to a recent research study "Allergy Immunotherapy Market, by immunotherapy Type (SCIT, SLIT), By Type of Allergy (Asthma, Food Allergy, Allergic Rhinitis and Others) opportunities and forecast 2020-2026" published by Data Library Research, the Allergy Immunotherapy Market Studies many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key…
Allergy Treatment Market Report 2018: Segmentation by Allergy Type (Food Allergy …
Global Allergy Treatment market research report provides company profile for Meda Pharmaceuticals Inc., Allergy Therapeutics, Sunovion Pharmaceuticals Inc., Allergon AB, Allergan, HAL Allergy Group, Teva Pharmaceutical and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Allergy Treatment Global Market 2018: Key Players – ALK, Stallergenes Greer, A …
Allergy Treatment Industry
Description
Wiseguyreports.Com Adds “Allergy Treatment -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database
This report studies the global Allergy Treatment market, analyzes and researches the Allergy Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
ALK
Stallergenes Greer
Allergy Therapeutics
HAL Allergy Group
Circassia
GlaxoSmithKline plc
Sunovion Pharmaceuticals
Teva Pharmaceutical Industries
Allergan plc
Allergon…
